BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...money as the company had raised privately. In July, Bridge granted Boehringer worldwide rights to BBT-877...
...round in April, the firm’s interest was driven by the ENPP2 inhibitor. “I believe that BBT-877...
...it enters Phase II.” Boehringer plans to start a Phase II trial next year of BBT-877...
BioCentury | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

...in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877...
...billion) in milestones, plus royalties up to double digits. The partners will collaborate to develop BBT-877...
BioCentury | Sep 7, 2018
Clinical News

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

...Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores...
...end for the small molecule inhibitor of autotaxin (ENPP2; ATX). The company said it believes BBT-877...
...Inc. (KOSDAQ:141080), Daejeon, South Korea Product: BBT-877 Business: Pulmonary Indication: Treat idiopathic pulmonary fibrosis (IPF) Brian Moy BBT-877 Bridge...
BioCentury | May 1, 2018
Distillery Therapeutics

Pulmonary

...pulmonary disease (COPD) and other pulmonary diseases. LegoChem Biosciences Inc. and Bridge Biotherapeutics Inc. have BBT-877...
BioCentury | Jun 16, 2017
Company News

LegoChem grants Bridge Biotherapeutics rights to autotaxin candidate

...up to KrW28 billion ($25.2 million) in milestones. Bridge Biotherapeutics will designate the compound as BBT-877...
...Biotherapeutics Inc. , Seongnam, South Korea Business: Pulmonary, Hepatic Chris Lieu Bridge Biotherapeutics Inc. LegoChem Biosciences Inc. Autotaxin (ENPP2) (ATX) BBT-877...
Items per page:
1 - 5 of 5